| Autor: |
Supper E; Experimental Cancer Genetics, Wellcome Sanger Institute, Hinxton, UK., Rudat S; Experimental Cancer Genetics, Wellcome Sanger Institute, Hinxton, UK., Iyer V; Experimental Cancer Genetics, Wellcome Sanger Institute, Hinxton, UK., Droop A; Experimental Cancer Genetics, Wellcome Sanger Institute, Hinxton, UK., Wong K; Experimental Cancer Genetics, Wellcome Sanger Institute, Hinxton, UK., Spinella JF; The Leucegene Project at Institute for Research in Immunology and Cancer, Université de Montréal, 2950 Chemin de Polytechnique Pavillon, Marcelle-Coutu, Montréal, QC, Canada., Thomas P; Experimental Cancer Genetics, Wellcome Sanger Institute, Hinxton, UK., Sauvageau G; The Leucegene Project at Institute for Research in Immunology and Cancer, Université de Montréal, 2950 Chemin de Polytechnique Pavillon, Marcelle-Coutu, Montréal, QC, Canada., Adams DJ; Experimental Cancer Genetics, Wellcome Sanger Institute, Hinxton, UK., Wong CC; Experimental Cancer Genetics, Wellcome Sanger Institute, Hinxton, UK. cw6@sanger.ac.uk.; Department of Haematology, Addenbrooke's Hospital, Cambridge, UK. cw6@sanger.ac.uk. |
| Abstrakt: |
While oncogenes promote tumorigenesis, they also induce deleterious cellular stresses, such as apoptosis, that cancer cells must combat by coopting adaptive responses. Whether tumor suppressor gene haploinsufficiency leads to such phenomena and their mechanistic basis is unclear. Here, we demonstrate that elevated levels of the anti-apoptotic factor, CASP8 and FADD-like apoptosis regulator (CFLAR), promotes apoptosis evasion in acute myeloid leukemia (AML) cells haploinsufficient for the cut-like homeobox 1 (CUX1) transcription factor, whose loss is associated with dismal clinical prognosis. Genome-wide CRISPR/Cas9 screening identifies CFLAR as a selective, acquired vulnerability in CUX1-deficient AML, which can be mimicked therapeutically using inhibitor of apoptosis (IAP) antagonists in murine and human AML cells. Mechanistically, CUX1 deficiency directly alleviates CUX1 repression of the CFLAR promoter to drive CFLAR expression and leukemia survival. These data establish how haploinsufficiency of a tumor suppressor is sufficient to induce advantageous anti-apoptosis cell survival pathways and concurrently nominate CFLAR as potential therapeutic target in these poor-prognosis leukemias. |
Full text from SpringerLink